Senti Biosciences Holdings, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

SNTI$0.14-11.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue - related party	$17	$—	$33	$—
Operating expenses:
Research and development (including related party costs of $3,516 and $3,586 for the three months ended June 30, 2026 and 2025, respectively, and $3,798 and $7,656 for the six months ended June 30, 2026 and 2025, respectively)	7,767	10,029	13,048	19,310
General and administrative	6,739	6,769	12,972	13,885
Gain on lease modification	—	—	(6,882)	—
Total operating expenses	14,506	16,798	19,138	33,195
Loss from operations	(14,489)	(16,798)	(19,105)	(33,195)
Other income:
Interest income	55	270	156	664
GeneFab sublease income - related party	996	1,586	1,076	3,299
Change in fair value of convertible notes - related party	271	—	271	—
Other income, net	417	209	631	387
Total other income	1,739	2,065	2,134	4,350
Net loss	$(12,750)	$(14,733)	$(16,971)	$(28,845)
Comprehensive loss	$(12,750)	$(14,733)	$(16,971)	$(28,845)
Basic and diluted net loss per share	$(0.41)	$(0.56)	$(0.55)	$(1.59)
Basic and diluted weighted-average number of shares used in computing net loss per share	31,144,754	26,081,273	31,058,642	18,091,478

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.